Guardant Health and Hikma Pharmaceuticals announced an agreement to promote Guardant Health’s portfolio of liquid and tissue biopsy tests for cancer screening, recurrence monitoring and tumor mutation profiling across all solid cancers in countries across the Middle East and North Africa, or MENA. The partnership expands Guardant Health’s global presence and includes products across the cancer care continuum. The tests offered include Shield for cancer screening and early detection, Guardant Reveal for minimal residual disease detection and recurrence monitoring, and Guardant360(R) and Guardant360 TissueNext(TM) for comprehensive genomic profiling across all solid cancers.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on GH:
- Guardant Health names Terilyn Juarez Monroe as chief people officer
- Guardant Health sells 3.387M shares at $26.77 in registered direct offering
- Guardant Health announces tentative date of FDA panel review of Shield test
- Guardant Health initiated with neutral view at Guggenheim, here’s why
- Guardant Health initiated with neutral view at Wolfe Research, here’s why
